Clinical trials are crucial in the development and testing of new treatment options for patients diagnosed with cancer, determining their safety and efficacy, and establishing a new standard of care.
Although today clinical trials are considered an instrumental part of drug development, the growth of studies to investigate and test new drugs, leading to a growing demand of trial participants, first started as part of a better understanding the science and medicine, leading to significant developments in the 19th and (early) 20th centuries that produced a multitude of novel medicinal products that required some form of testing.
A regulatory framework takes shape
The development of a regulatory framework of testing novel drugs followed. First with basic regulations included in the Food and Drug Act of 1906, the first federal law to regulate food and drugs designed to prevent the sale of misbranded or adulterated food and drugs and was a established as the result of public outcry over unsafe food products and medicines. The act established the Bureau of Chemistry, which later evolved into the US Food and Drug Administration.
Although the Food and Drug Act of 1906, was relatively clear about drug standards, misbranding of drugs became a source of considerable controversy in drug regulation, leading to a growing number of untested drugs or drugs labeled with false therapeutic claims intended to defraud consumers. With the election of Franklin D. Roosevelt in 1932, work began replace the outdated law. The new law legally mandated quality and identity standards, and required that drugs should be labeled with adequate directions for safe use, The new law also required pre-market approval of all new drugs and required manufacturers to prove that a drug was safe before it could be marketed.
Congress did not pass the bill that would ultimately replace the obsolete 1906 law until a therapeutic disaster in 1937 resulted in the death of over 100 people. A public outcry that followed this therapeutic disaster not only reshaped the drug provisions of the new law to prevent such an event from happening again, but, after 5 ling years of delays, also propelled the bill through Congress. Franklin D. Roosevelt signed the Food, Drug, and Cosmetic Act on June 25, 1938.
Between 1940s and 1950s clinical trials started to incorporate most of the essential elements, common today trial design, including control groups, randomization, and blinding. However, it took yet another therapeutic disaster that to further improve the drug development and clinical trials.
In 1962, following the Thalidomide-disaster, a new drug law, the Kefauver-Harris Amendments, derived from hearings held by Senator Estes Kefauver, resulted in a much stricter law than existed before. The new law not only required proof of safety for new drugs, but also required substantial evidence of efficacy based on adequate and well-controlled clinical studies. In the years that followed, strict regulations for the ethical conduct of clinical research and the rules to protect study participants were adopted.
A gold standard
Today, the review process for novel drugs in the United States is recognized worldwide as the gold standard. Before they can be marketed they must undergo a rigorous evaluation of safety, quality, and effectiveness. Clinical trials provide this data on how novel, investigational drugs work before they are approved by regulatory authorities such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others.
In many instances, clinical trials not only help determine if new treatment approaches are more effective, improving the health-related Quality of Life (hrQoL) of patients and survival outcomes, investigate if investigational agents have fewer adverse effects or offer a superior treatment compared to the current standard of care; they also explore methods for cancer prevention, test new screening tools, or, using advances in genomic and molecular sequencing, test targeted agents and immunotherapies in specific patient subsets based on biomarkers, or allow researchers to identify which genetic aberrations are most vulnerable to certain drugs.
Adaptive clinical trials
Traditional clinical trials relied upon a relatively standardized battery of preclinical tests followed by clearly defined and generally understood sequential clinical development steps requiring a large number of patients with extended follow-up to meet discrete predefined regulatory milestones as are necessary for drug approval.
In contrast, a newer paradigm for drug development involves adaptive clinical trial designs that incorporate real-world evidence and big data to address common challenges in oncology drug development, including slow patient enrollment, tumor heterogeneity, and acquired treatment resistance. In simple terms, the adaptive trial design is a method that utilizes accumulating data to modify the trial’s course. Such a trial design, which allows the same information to be generated as traditional clinical trials, but in a more efficient manner, is ideal for addressing many questions at once.[1]
For example, a single adaptive clinical trial might identify the appropriate patient population, dose, and regimen, as well as therapeutic combinations, and then switch seamlessly into a phase 3 confirmatory trial. The benefits of such an approach are abundantly evidenced by the I-SPY and I-SPY 2 clinical trials, which evaluate drugs from multiple companies in the same trial.[2]
Improving Overall Survival
Because of the progress made through past clinical trials, survival rates for many cancers have dramatically improved. For example, clinical trials were responsible for raising the survival rate for Hodgkin lymphoma from 15% in 1950 to nearly 90% today.
Clinical trials also directly benefit patients participating in them. One reason is that participating patients are generally more closely monitored. This collaborative partnership approach empowers patients to play an active role in their care, while, at the same time, contributing to scientific knowledge, crucial for the ongoing development of novel treatment options.
To ensure fair health outcomes, the FDA requires that clinical trials include people and populations from different racial and ethnic backgrounds, including women and children. This was a significant shift from historical policies that often excluded these populations from research. [3][4]
Barriers to accessing clinical trials
However, despite the importance of clinical trials in oncology, many patients face barriers to accessing them, resulting in limited trial enrollment. Although barriers are observed in virtually all types of clinical trials and for all forms of cancer, barriers may be more noticeable in rare cancers, which account for nearly 25% of all diagnosed cancers.[5]
Limited clinical trial enrollment – a major barrier that limits patient participation – can also be caused by excessively restrictive inclusion and exclusion criteria, which are, for example, seen among the barriers for patients diagnosed with myelodysplastic syndromes/neoplasms (MDSs), a group of blood disorders characterized by abnormal blood cell production in the bone marrow, and may progress to acute myeloid leukemia (AML). Although multiple organizations are working to increase clinical trial eligibility for patients diagnosed with MDS, several recent publications suggest that many patients may still be unnecessarily excluded from clinical trial participation. [6]
Other barriers
A new collaboration between Blood Cancer United®* and The US Oncology Network aims to expand clinical trial education and navigation, helping more patients across the country explore trials as a possible treatment option.
Blood Cancer United, the largest global nonprofit dedicated to blood cancer patient support, research, and advocacy, and The US Oncology Network, an organization of independent, community-based providers supported by McKesson, will partner to enhance education about blood cancer clinical trials in select cities, including how to find and access suitable trials. The collaboration will include personalized clinical trial education via Blood Cancer United’s Clinical Trial Support Center, as well as clinical trial matching through The US Oncology Network’s partnership with Sarah Cannon Research Institute, and patient navigation services to facilitate participation in clinical trials for patients with all types of blood cancer.
“We are committed to supporting patients by identifying and removing barriers to clinical trial enrollment,” said Gwen Nichols, M.D., Chief Medical Officer of Blood Cancer United. “Collaborations such as this one have great potential to improve patient outcomes directly.”
A pilot program
Blood Cancer United and The US Oncology Network have launched a two-year pilot program at participating sites across three states. Patients at the participating sites will have access to the Clinical Trial Support Center’s resources by the end of 2025.
“It’s incredibly powerful to see our organizations collaborate around a shared goal — strengthening cancer care and access to clinical trials close to home, in communities across the nation,” noted Devon Womack, president of The US Oncology Network.
“By expanding education around clinical research, we’re not just increasing trial enrollment — we’re opening doors to new possibilities, empowering patients with more treatment options, and ultimately, offering renewed hope in their fight against cancer,” Womack concluded.
__
Note: * Blood Cancer United® formerly The Leukemia & Lymphoma Society
Clinical trials
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY) – ClinicalTrials.gov ID NCT01042379
Reference
[1] Porcher R, Lecocq B, Vray M; participants of Round Table N° 2 de Giens XXVI. Adaptive methods: when and how should they be used in clinical trials? Therapie. 2011 Jul-Aug;66(4):319-26, 309-17. English, French. doi: 10.2515/therapie/2011042. Epub 2011 Aug 19. PMID: 21851793.
[2] Wang H, Yee D. I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer. Curr Breast Cancer Rep. 2019 Dec;11(4):303-310. doi: 10.1007/s12609-019-00334-2. Epub 2019 Nov 20. PMID: 33312344; PMCID: PMC7731787.
[3] Wang T, Villanueva DJ, Banerjee A, Gifkins D. Reporting and representation of participant race and ethnicity in phase III clinical trials for solid tumors. Future Sci OA. 2025 Dec;11(1):2458415. doi: 10.1080/20565623.2025.2458415. Epub 2025 Jan 30. PMID: 39885684; PMCID: PMC11792851.
[4] Wang T, Banerjee A, Gifkins D. Reporting and representation of race and ethnicity data in phase III clinical trials for hematological malignancies. Future Sci OA. 2025 Dec;11(1):2563483. doi: 10.1080/20565623.2025.2563483. Epub 2025 Sep 22. PMID: 40980857; PMCID: PMC12456206.
[5] van der Graaf WTA, Heiss NS, Hynes CL, Keller SP, Weinman A, Blay JY, Franco P, Giles RH, Lacombe D, Schlatter P, Thomas DM, van Waalwijk van Doorn-Khosrovani SB, Williamson M, Plummer R. Overcoming the barriers to treatment of rare cancer patients in the era of precision oncology: A call to action. Cancer Treat Rev. 2025 Nov;140:103013. doi: 10.1016/j.ctrv.2025.103013. Epub 2025 Aug 14. PMID: 40902364.
[6] Borate U, Pugh K, Waller A, Welkie RL, Huang Y, Bewersdorf JP, Stahl M, DeZern AE, Platzbecker U, Sekeres MA, Wei AH, Buckstein RJ, Roboz GJ, Savona MR, Loghavi S, Hasserjian RP, Fenaux P, Sallman DA, Hourigan CS, Della Porta MG, Nimer S, Little RF, Santini V, Efficace F, Taylor J, Garcia-Manero G, Odenike O, Kim TK, Halene S, Komrokji RS, Griffiths EA, Greenberg PL, Xu ML, Xie Z, Bejar R, Sanz GF, Patnaik MM, Figueroa M, Carraway HE, Abdel-Wahab O, Starczynowski D, Padron E, Boultwood J, Gore S, Daver NG, Churpek JE, Majeti R, Bennett JM, List AF, Brunner AM, Zeidan AM. Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement. Blood. 2025 Mar 27;145(13):1369-1381. doi: 10.1182/blood.2023023717. PMID: 40146152; PMCID: PMC11969261.
Featured image courtesy © 2017 – 2025 Fotolia/Adobe. Used with permission.
DOI





